RSVpreF vaccine

Alternative Names: Abrysvo

The RSVpreF vaccine is a shot that helps protect newborn babies and older adults from getting very sick from RSV (Respiratory Syncytial Virus). It works by training the body to fight off the virus before it causes serious problems. The vaccine is given to pregnant women between weeks 32 and 36 of pregnancy, so their baby is born with protection during their first RSV season. It is also approved for adults aged 60 and older to help prevent lung infections like pneumonia. In studies, the vaccine reduced the risk of severe RSV illness by about 80% in babies and around 85% in older adults.

Treatment Type: Prescription Medication

Treatment Class: N/A

Treatment Modality: N/A

RSVpreF vaccine

Review Summary

5.0

1 Reviews

Preferred by 1 Reviewers

Based on the single review provided, the RSVpreF vaccine appears to be highly effective in reducing the risk of severe RSV (Respiratory Syncytial Virus) in the approved populations. The reviewer, Dr. Curbside, gave the vaccine a rating of 5 out of 5, suggesting that it is a highly promising treatment for preventing severe RSV infections.

This summary was generated by users' reviews

Breakdown by Category

Each categories are rated on a 1–5 scale, with 5 being the most favorable outcome and 1 being the least. These scores are averaged across all user reviews to provide a clear sense of how this treatment typically performs in each area.

Cost
3.0
1 = Very Expensive 5 = Very Affordable

3.0

Moderate Cost
Relief Speed
2.0
1 = No Relief 5 = Immediate Relief

2.0

Slow Relief
Side Effects
4.0
1 = Intolerable Effect 5 = No Effect

4.0

Mild Effect
Treatment Line
5.0
1 = Third-line or more 5 = First-line

5.0

First-line

Explore various treatment options to empower yourself in making a well-informed choice.

Choose treatments from the menu above to see how they compare side by side.

Choose treatments from the menu above to see how they compare side by side.

Choose treatments from the menu above to see how they compare side by side.

5.0

1 Reviews
5
100%
4
0%
3
0%
2
0%
1
0%

AI Summary of User Experiences

Not medical advice.

Based on the single review provided, the RSVpreF vaccine appears to be highly effective in reducing the risk of severe RSV (Respiratory Syncytial Virus) in the approved populations. The reviewer, Dr. Curbside, gave the vaccine a rating of 5 out of 5, suggesting that it is a highly promising treatment for preventing severe RSV infections.

Reviews

Filter by reviewer type Pro

Select all Clear all

Cost
Very Expensive
$1000+
Expensive
$501 to $1000
Moderate Cost
$101 to $500
Affordable
$25 to $100
Very Affordable
$25
Relief Speed
No Relief
No noticeable improvement
Slow Relief
Several days to weeks
Moderate Relief
Within 1 - 3 days
Fast Relief
Within hours
Immediate Relief
Within minutes
Side Effect
Intolerable Side Effect
Caused treatment to stop or required hospitalization
Severe Side Effect
Difficult to tolerate, may require intervention
Moderate Side Effect
Noticeable, but manageable
Mild Side Effect
Minor, not bothersome
No Side Effect
Without any adverse effects
Treatment Line
Third-line or more
Used after second-line failed or multiple prior treatment
Second-line
Used after first-line treatment failed or was unsuitable
First-line
First treatment tried
Dr. Curbside

Dr. Curbside

Verified
Physician • Emergency Medicine • How doctors think about decisions — and what real-world experiences add
3 months ago
RSVpreF (Abrysvo) is one of the most effective options to prevent severe RSV disease, particularly in older adults and in pregnancy to protect newborns. It works by generating antibodies against the RSV prefusion F protein, which helps reduce the risk of hospitalization and serious complications. Overall, it’s a key preventive tool, especially for higher-risk groups during RSV season.
#ModerateCost #CoveredByInsurance #SlowRelief #MildEffect #First-line #Preventative
View Professional Disclosures

Copyright © 2025,Curbside and related marks are registered trademarks of Curbside Tech Inc.

We use cookies to personalize our services and provide you with the best possible experience. By continuing to use this site, you agree to this cookie usage. We also use third-party cookies that help us analyse how you use this website, store your preferences, and provide the content and advertisements that are relevant to you. These cookies will only be stored in your browser with your prior consent. You can learn more about cookies and how your data is processed in the Privacy Policy.

Strictly Necessary Only Accept All